This is a Pfizer news story, published by CNBC, that relates primarily to Covid news.
For more Pfizer news, you can click here:
more Pfizer newsFor more Covid news, you can click here:
more Covid newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
Covid vaccines. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Covid vaccine news, new flu vaccines news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
previous vaccinationsCNBC
•
86% Informative
The FDA approves updated Covid vaccines from Pfizer and Moderna .
The jabs target a strain called KP.2 , a descendant of the highly contagious omicron subvariant JN.1.
Pfizer will begin shipping its new shot immediately.
Moderna expects its shot to be available in the coming days .
VR Score
90
Informative language
92
Neutral language
21
Article tone
formal
Language
English
Language complexity
52
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
7
Source diversity
5
Affiliate links
no affiliate links